BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:precemtabart tocentecan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of precemtabart tocentecan\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06710132-2612@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20271223
DTEND;VALUE=DATE:20271224
SUMMARY:precemtabart tocentecan: Phase 1/2 readout est. (NCT06710132)
DESCRIPTION:precemtabart tocentecan\, phase 1/2\, Non-Small Cell Lung Cance
 r.\nStudy: Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced S
 olid Tumors (PROCEADE PanTumor)\nEstimated primary completion: 23 December
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/precemtabart-t
 ocentecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06710132
URL:https://assetmemo.bio/drug/precemtabart-tocentecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07549412-2612@assetmemo.bio
DTSTAMP:20261121T005637Z
DTSTART;VALUE=DATE:20291016
DTEND;VALUE=DATE:20291017
SUMMARY:precemtabart tocentecan: Phase 3 readout est. (NCT07549412)
DESCRIPTION:precemtabart tocentecan\, phase 3\, Metastatic Colorectal Cance
 r.\nStudy: A Study of Precemtabart Tocentecan With or Without Bevacizumab 
 Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With P
 reviously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)\nEstimate
 d primary completion: 16 October 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/precemtabart-tocentecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07549412
URL:https://assetmemo.bio/drug/precemtabart-tocentecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
